Thalidomide and its analogues in the treatment of Multiple Myeloma

被引：0
作者：
Tahir Latif
Nabeel Chauhan
Rashid Khan
Andrea Moran
Saad Z Usmani
机构：
[1] University of Cincinnati School of Medicine,UC Cancer Institute, Division of Hematology
[2] University of Arkansas for Medical Sciences,Oncology
[3] University of Connecticut Health Center,Myeloma Institute for Research & Therapy
来源：
Experimental Hematology & Oncology | / 1卷 / 1期
关键词：
Multiple Myeloma; Thalidomide; Lenalidomide; Pomalidomide; Therapy;
D O I：
10.1186/2162-3619-1-27
中图分类号：
学科分类号：
摘要：
Multiple myeloma is an incurable malignant disorder of mature B-cells that predominantly affects the elderly. The immunomodulatory drug (IMiD) thalidomide and its newer analogs demonstrate increased antitumor activity, and have had a positive impact on the natural history of multiple myeloma. Recent advances in the clinical application of these agents and in our understanding of their mechanism of action, and toxicity have made safer and smarter use of these drugs possible. This review discusses the available information regarding mechanisms of action, toxicity and clinical results on thalidomide, lenalidomide and pomalidomide in the therapy of multiple myeloma.
引用
收藏
相关论文
共 172 条
[1]  
Kyle RA(2004)Multiple Myeloma N Engl J Med 351 1860-1873
[2]  
Rajkumar SV(2011)Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J Clin 61 212-236
[3]  
Siegel R(1844)Remarks on the pathology of mollities ossium with cases Med Chir Trans 27 435-498
[4]  
Ward E(1982)The current status and future prospects of treatment for multiple myeloma Clinic in Haematology 11 181-210
[5]  
Brawley O(1958)Clinical Experiences With Sarcolysin In Neoplastic Diseases Ann N Y Acad Sci 68 1128-1132
[6]  
Jemal A(1962)A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma Cancer Chemother Rep 1 16 257-259
[7]  
Solly S(1986)Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results Semin Oncol 13 318-325
[8]  
Durie BGM(1999)Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1565-1571
[9]  
Salmon SE(2003)Treatment of plasma cell dyscrasias with thalidomide and its derivatives J Clin Oncol 21 4444-4454
[10]  
Blokhin N(2004)Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity Mayo Clin Proc 79 875-882
12345678910